Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Chlorogenic acid - Sichuan J.Z. Bio-chemical Science and Technology Development

Next Previous
Drug Profile

Chlorogenic acid - Sichuan J.Z. Bio-chemical Science and Technology Development

Alternative Names: 3-caffeoylquinic-acid ; 3-O-caffeoylquinic-acid ; Coffee tannic acid; Hlorogenic-acid

Latest Information Update: 30 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sichuan J.Z. Bio-chemical Science and Technology Development Co
  • Class Antineoplastics; Cinnamates; Cyclohexanecarboxylic acids; Esters; Small molecules
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Glioblastoma
  • Phase I/II Non-small cell lung cancer; Small cell lung cancer
  • No development reported Cancer

Most Recent Events

  • 05 Mar 2021 Chlorogenic acid is still in Phase-II/III clinical trials in Glioblastoma in China (Parenteral)
  • 05 Mar 2021 Chlorogenic is still in Phase-I/II clinical trials in Small cell lung cancer and Non-small cell lung cancer in China (IM)
  • 10 Dec 2018 Phase-II/III clinical trials in Glioblastoma (Late-stage disease, Second-line therapy or greater) in China (Parenteral) (NCT03758014)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top